• Reviva Pharmaceuticals Holdings, Inc. RVPH.OQ reported a quarterly adjusted loss of 25 cents​​ per share for the quarter , higher than the same quarter last year, when the company reported EPS of -44 cents. The mean expectation of six analysts for the quarter was for a loss of 25 cents per share. Wall Street expected results to range from -31 cents to -20 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Reviva Pharmaceuticals Holdings, Inc.'s reported EPS for the quarter was a loss of 25 cents​.

• The company reported a quarterly loss of $8.37 million.

• Reviva Pharmaceuticals Holdings, Inc. shares had fallen by 16.0% this quarter and lost 76.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 12.9% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Reviva Pharmaceuticals Holdings, Inc. is $15.00

This summary was machine generated from LSEG data November 15 at 02:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)